Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-12-02
2011-12-06
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100
Reexamination Certificate
active
08071324
ABSTRACT:
Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.
REFERENCES:
patent: 4394448 (1983-07-01), Szoka et al.
patent: 4442124 (1984-04-01), Niklaus
patent: 4595695 (1986-06-01), Ladkani et al.
patent: 4798823 (1989-01-01), Witzel
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4885276 (1989-12-01), Witzel
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 4914188 (1990-04-01), Dumont et al.
patent: 5122511 (1992-06-01), Patchett et al.
patent: 5162573 (1992-11-01), Chiesi et al.
patent: 5214130 (1993-05-01), Patchett et al.
patent: 5225539 (1993-07-01), Winter
patent: 5227467 (1993-07-01), Durette et al.
patent: 5236899 (1993-08-01), Durette
patent: 5440023 (1995-08-01), Cheng et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5585358 (1996-12-01), Bialer et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633426 (1997-05-01), Namikawa et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5874299 (1999-02-01), Lonberg et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6268396 (2001-07-01), Nau et al.
patent: 6313106 (2001-11-01), Kozak
patent: 6323365 (2001-11-01), Blaler et al.
patent: 6458840 (2002-10-01), Nau et al.
patent: 6555585 (2003-04-01), Shirvan et al.
patent: 6602684 (2003-08-01), Umana et al.
patent: 6809077 (2004-10-01), Or et al.
patent: 7141648 (2006-11-01), Naicker et al.
Konety et al, J Urology, 2001, 165:600-611.
Rogers et al, Cancer Res, 2003, 63:6971-6983.
Collier et al., “Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse”,Nature, 436:272-276 (2005).
Dupuy et al., “Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system”,Nature, 436:221-226 (2005).
Ficarra et al., “TNM staging system for renal-cell carcinoma: current status and future perspectives”,Lancet Oncology, 8(6):554-558 (2007).
Hadjantonakis et al., “mCelsr1 is an evolutionarily conserved seven-pass transmembrane receptor and is expressed during mouse embryonic development”,Mech Dev., 78:91-5 (1998).
Hadjantonakis, A. K. et al., “Celsr1, a neural-specific gene encoding an unusual seven-pass transmembrane receptor, maps to mouse chromosome 15 and human chromosome 22qter”,Genomics, 45:97-104 (1997).
Li, J. et al., “Leukaemia disease genes: large-scale cloning and pathway predictions”,Nat Genet., 23:348-53 (1999).
Lovmand, J. et al., “B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer”,J Virol., 72:5745-56 (1998).
Lund et al., “Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice”,Nat Genet, 32:160 (2002).
Mikkers et al. “High-throughput retroviral tagging to identify components of specific signaling pathways in cancer”,Nat Genet, 32:153-159 (2002).
Nusse et al., “Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15”,Nature, 307:131-136 (1984).
Nusse, R., and H. E. Varmus, “Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome”,Cell31:99-109 (1982).
Sorensen et al., “Sequence tags of provirus integration sites in DNAs of tumors induced by the murine retrovirus SL3-3”,J Virol, 70:4063-4070 (1996).
Suzuki, T. et al. “New genes involved in cancer identified by retroviral tagging”,Nat Genet., 32:166-74 (2002).
Tissir et al., “Developmental expression profiles of Celsr (Flamingo) genes in the mouse”,Mech Dev., 112:157-60 (2002).
Tockman et al. “Considerations in bringing a cancer biomarker to clinical application”,Cancer Research, 52:2711S-2718S (1992).
van Lohuizen, M. et al., “Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging”,Cell, 65:737-52 (1991).
Wu, Q. & Maniatis, T., “Large exons encoding multiple ectodomains are a characteristic feature of protocadherin genes”,Proc Natl Acad Sci U S A, 97:3124-9 (2000).
Wabl Matthias
Wang Bruce
Bennett Dennis A.
Halvorson Mark
Picobella, LLC
Yu Misook
LandOfFree
Methods for diagnosing and treating kidney cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for diagnosing and treating kidney cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing and treating kidney cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4270005